Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.62 |
| ▸ | CTSS | P25774 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | CCKBR | P32239 | 5/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1271407 | 0.93 | CTSL (0.61) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL1270433 | 0.86 | CTSL (0.57) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL1270426 | 0.83 | KDM4E (0.53) | CTSLMAPTBCHEACHE | |
| SCHEMBL30643020 | 0.82 | CTSL (0.67) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL29419170 | 0.82 | CTSL (0.77) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL21286953 | 0.82 | CTSL (0.77) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL30375072 | 0.82 | CTSL (0.80) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL21269082 | 0.82 | CTSL (0.77) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL31360963 | 0.81 | CTSL (0.63) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL645235 | 0.81 | ACE (0.66) | CTSLCTSSCTSKMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110038885-A1 | CHEMOKINE ANALOGS | IPSEN PHARMA S.A.S. (FR) | 2011-02-17 | — | — | US | claimed |
| JP-2010534652-A | — | — | 2010-11-11 | — | — | JP | claimed |
| EP-2182973-A1 | CHEMOKINE ANALOGS | IPSEN PHARMA S.A.S. (FR) | 2010-05-12 | — | — | EP | claimed |
| WO-2009017620-A1 | CHEMOKINE ANALOGS | IPSEN PHARMA S.A.S. (FR) | 2009-02-05 | — | — | WO | claimed |
| US-20110038885-A1 | CHEMOKINE ANALOGS | IPSEN PHARMA S.A.S. (FR) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038885-A1 | CHEMOKINE ANALOGS | CCL11, CCL5, CCL2 | CTSL 140/4885CTSS 1067/4885CTSK 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.